A Study to Evaluate the Q Revascularization System for Neurointervention in Acute Ischemic Stroke

Inclusion Criteria: * Age 18 years or older. * Pre-stroke independent functional status in activities of daily living with mRS 0-1. * A disabling stroke defined as NIHSS ≥ 6 * In USA thrombolytic therapy (IV tPA) received within 3 hours of onset/ last known well, in Europe treatment with IV tPA received within 4.5 hours from onset/ last known well OR ineligibility for thrombolytic therapy * Endovascular treatment intended to be initiated \< 8 hours from onset of symptoms or last known well time * Confirmed symptomatic large vessel occlusion of the intracranial internal carotid artery, middle cerebral artery, M1, M2, basilar or intracerebral vertebral artery by baseline neuroimaging CTA/MRA and angiographic imaging with a mTICI Score 0-1 * For strokes in the anterior circulation the following imaging criteria should also be met: MRI criterion of volume of diffusion restriction visually assessed ≤50 mL OR CT criterion of ASPECTS 6 to 10 on baseline CT or CTA-source images or, significantly lowered cerebral blood volume (CBV) ≤50 mL * For strokes in the basilar or vertebral artery, the following imaging criterion should also be met: pc-ASPECTS score 8 to 10 on baseline CT, CTA-source images, or MRI * Signed informed consent from subject, acceptable person responsible (e.g. LAR) and/or according to County specific regulatory requirements and local ethical committee or review board requirements Exclusion Criteria: * CT or MRI evidence of intracranial hemorrhage on presentation * CT or MRI showing mass effect or intracranial tumor (meningioma \> 2 cm in diameter). * Previous stroke within the past 3 months * Rapidly improving neurological status as determined by Investigator/Neurologist * Renal failure/insufficiency with \>3.0 mg/dL creatinine prior to procedure * Severe, sustained hypertension resistant to treatment (SBP \>185 mmHg or DBP \>110 mmHg) * Use of warfarin anticoagulation with International Normalized Ratio (INR) \> 3.0 at the time of the procedure or any known hemorrhagic or coagulation deficiency * For patients who have received a direct thrombin inhibitor within the last 48 hours; partial thromboplastin time (PTT) \> 2.0 times the normal prior to procedure * Platelet count \< 50,000 mm3 * Cerebral vasculitis or evidence of active systemic infection * Suspicion of aortic dissection, presumed septic embolus, or suspicion of bacterial endocarditis * Clinical symptoms suggestive of bilateral stroke or occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation) * Seizure due to stroke * Pregnancy * Severe contrast allergy or absolute contraindication to iodinated contrast * Presence of a carotid artery stenosis or occlusion requiring balloon angioplasty or stenting at time of the procedure * Difficult endovascular access or difficult aortic arch or severe neurovascular tortuosity that will result in an inability to deliver endovascular therapy * Evidence of dissection in the carotid or target artery for treatment * Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic * Active participation in another study involving an investigational drug or device * A severe or fatal comorbid illness that will prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient * Unwillingness to complete follow up visits